Litcius/Paper detail

Ruxolitinib combined with doxorubicin, etoposide, and dexamethasone for the treatment of the lymphoma-associated hemophagocytic syndrome

Lanlan Zhou, Yanan Liu, Zhenzhen Wen, Shimei Yang, Mingjie Li, Qiuhua Zhu, Shiqiu Qiu, Yanmin Gao, Hong Wang, Yuemei Yuan, Hanling Zhang, Chaolun Chen, Wenbin Zeng, Zebing Guan, Xueyi Pan

2020Journal of Cancer Research and Clinical Oncology47 citationsDOIOpen Access PDF

Topics & Concepts

MedicineInternal medicineRuxolitinibEtoposideHazard ratioDexamethasoneHemophagocytic lymphohistiocytosisGastroenterologyRegimenLymphomaHematologyConfidence intervalChemotherapySurgeryMyelofibrosisBone marrowDiseaseAutoimmune and Inflammatory Disorders ResearchLymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research
Ruxolitinib combined with doxorubicin, etoposide, and dexamethasone for the treatment of the lymphoma-associated hemophagocytic syndrome | Litcius